Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.64898/2026.04.20.719605

Mechanisms controlling the deposition and dynamics of histone variant H2BE

Sangree, A. K.·Feierman, E. R.·Perez-Tremble, R.·Korb, E.
View original source ↗Export metadata ↓

Abstract

Histone variants shape chromatin structure and gene regulation and their deposition and localization in chromatin are tightly controlled. H2BE is the only known widely expressed mammalian H2B variant and localizes to transcription start sites to control chromatin accessibility and cognitive function. However, the mechanisms governing H2B variant incorporation into chromatin remain unclear. Here, we define the regulatory framework controlling H2BE incorporation, localization, and eviction in neuronal chromatin. We identify the BAF remodeling complex and the transcription factor SP1 as key drivers of H2BE deposition at specific genomic loci. We further show that FACT maintains H2BE enrichment at transcription start sites by preventing its distribution into gene bodies, while the histone chaperone NAP1L4 mediates H2BE eviction from chromatin. Comparative analysis with H2A.Z reveals that BAF, SP1 and NAP1L4 exert H2BE-specific functions, while FACT functions more broadly across histone variants. Finally, we define the H2BE-dependent transcriptional effects of it chaperones. Together, these findings uncover the first chaperones governing H2B variant incorporation and define a highly complex mechanism responsible for H2BE regulation in chromatin. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=200 SRC="FIGDIR/small/719605v1_ufig1.gif" ALT="Figure 1"> View larger version (36K): org.highwire.dtl.DTLVardef@199fd10org.highwire.dtl.DTLVardef@b561c1org.highwire.dtl.DTLVardef@24ef4corg.highwire.dtl.DTLVardef@da8152_HPS_FORMAT_FIGEXP M_FIG C_FIG HighlightsO_LIThe BAF complex controls H2BE incorporation. C_LIO_LISP1 promotes locus-specific incorporation of H2BE. C_LIO_LIFACT prevents H2BE accumulation in genic regions. C_LIO_LINAP1L4 mediates eviction of H2BE from chromatin. C_LI

Explore related subjects

geneticsPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Sangree, A. K., Feierman, E. R., Perez-Tremble, R., Korb, E.. 2026-04-22. Mechanisms controlling the deposition and dynamics of histone variant H2BE. https://doi.org/10.64898/2026.04.20.719605

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD

Progressive hepatic fibrosis is the principal determinant of morbidity and mortality in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Mitochondrial dysfunction is a hallmark of MASH, and the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from injured hepatocytes can promote fibrosis. However, how mitochondrial dynamics and quality control shape the fibrotic response in MASLD/MASH remains unclear. Here, through large-scale genomic analyses of mitochondrial genes governing mitophagy, fusion and fission in human MASLD, with a power-equivalent sample size of approximately 700,000 individuals, we identify a strong association between hepatic fibrosis and the mitochondrial fusion factor dynamin-like GTPase optic atrophy 1 (OPA1). OPA1 transcripts and protein abundance in the liver epithelium were progressively dysregulated with advancing fibrosis. In mice, hepatocyte-specific OPA1 loss alone was sufficient to induce hepatic stellate cell activation and fibrosis in zone 3, promoted the release of mito-DAMPs into the circulation and exacerbated fibrosis in experimental MASH. These findings identify OPA1 as a central regulator of the hepatic fibrotic response and connect defective mitochondrial homeostasis to mito-DAMP release, hepatic stellate cell activation and fibrosis in MASLD.

genetics↗
bioRxiv2026

Mechanism-selective deep mutational scanning distinguishes ERCC2 disease phenotypes

Pathogenic ERCC2 variants cause xeroderma pigmentosum (XP), trichothiodystrophy (TTD) or both, yet variant effect scores are usually interpreted only as measures of pathogenicity rather than of which disease mechanism is disrupted. XPD, the ERCC2-encoded TFIIH subunit, functions in both nucleotide excision repair and transcription. Using yeast complementation deep mutational scanning, we measured the effects of nearly all XPD amino acid substitutions. The assay was mechanism-selective: it preferentially reported transcription-associated function, with pronounced intolerance at the p44 interface, whereas many substitutions affecting DNA binding and helicase activity retained near-wild-type fitness. Accordingly, TTD variants had much lower fitness than XP variants. Computational predictors discriminated pathogenic from benign variants similarly across phenotypes, but the DMS distinguished XP from TTD variants better than all 73 predictors tested. Phenotype-specific ACMG/AMP calibration provided evidence in both directions for TTD but mainly pathogenic evidence for XP. Thus, the selectivity of functional assays, often viewed as a limitation, can reveal disease mechanisms and support phenotype-aware variant interpretation.

genetics↗
bioRxiv2026

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

genetics↗